PLoS Pathogens:流感病毒与宿主的相互作用研究方面取得新进展

2022-09-15 “生命科学前沿”公众号 “生命科学前沿”公众号

A型流感病毒有效地劫持细胞内“资源”以完成自身转录和复制,这涉及病毒和宿主蛋白之间的广泛相互作用。

近日,南京农业大学动物医学院平继辉教授课题组在国际学术期刊 PLoS Pathogens发表题为“TREX (transcription/export)-NP complex exerts a dual effect on regulating polymerase activity and replication of influenza A virus”。 该项研究首次阐明了TREX (transcription/export)-NP复合物在调节流感病毒聚合酶活性方面发挥了双重作用。

A型流感病毒(IAV)和新型冠状病毒(SARS-CoV-2)等病毒病原体的传播给全球经济和人类健康带来了巨大的挑战。探索IAV与宿主的相互作用可加深我们对病毒病发病机制的深层次认知,并促进抗病毒新疗法的开发。

A型流感病毒有效地劫持细胞内“资源”以完成自身转录和复制,这涉及病毒和宿主蛋白之间的广泛相互作用。通过质谱技术及生信分析,本研究筛选了属于DExD/H-box蛋白家族成员、RNA结合蛋白以及线粒体锚定蛋白的宿主因子,揭示它们对流感病毒聚合酶活性的影响。发现RNA解旋酶DDX39B和DDX39A参与调节流感病毒聚合酶活性,影响甲型流感病毒的复制。

本研究进一步揭示了DDX39B和DDX39A与病毒NP和NS1蛋白相互作用。有趣的是,病毒NP蛋白可以逆转过量DDX39B或DDX39A对聚合酶活性的抑制作用。

机制上,TREX复合物亚基 THOC1、THOC4和CIP29通过与DDX39B或DDX39A的相互作用,以ATP依赖的方式被招募到DDX39B-DDX39A-NP复合物中。然而过量的TREX-NP复合物干扰正常的NP寡聚化状态,这取决于病毒蛋白和宿主蛋白之间的比例。

图片

TREX复合物是一种进化上保守的蛋白复合物,负责整合多个mRNA加工步骤以输出病毒mRNA。敲减TREX复合物亚基会显着下调病毒滴度和蛋白水平,同时导致病毒mRNA滞留在细胞核中。

综上,筛选调节流感病毒复制的宿主因子可以促进我们对病毒发病机理的理解,并靶向性设计和研发新型抗病毒药物,本研究揭示了之前未阐明的TREX复合物参与流感病毒复制的调控机制。

南京农业大学动物医学院平继辉教授为该论文通讯作者,该学院博士研究生赵令才为论文第一作者,博士研究生刘清政和卢渊录,以及硕士生黄镜瑾和赵永振参与了该研究的相关工作。该研究得到了国家重点研发计划 (2021YFD1800205)、国家自然科学基金面上项目(31772775) 以及国家兽医生物技术重点实验室开放课题(SKLVBF202103)的资助。

原始出处:

Lingcai Zhao, Qingzheng Liu, Jingjin Huang, et al. TREX (transcription/export)-NP complex exerts a dual effect on regulating polymerase activity and replication of influenza A virus. PLoS Pathogens, 2022.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1786130, encodeId=56391e861307d, content=<a href='/topic/show?id=e30813e89e2' target=_blank style='color:#2F92EE;'>#Pathogens#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13789, encryptionId=e30813e89e2, topicName=Pathogens)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Sun May 14 19:44:44 CST 2023, time=2023-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909345, encodeId=39081909345e6, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Mar 07 02:44:44 CST 2023, time=2023-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404791, encodeId=747f1404e91aa, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Fri Sep 16 04:44:44 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471718, encodeId=accc14e17186e, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Fri Sep 16 04:44:44 CST 2022, time=2022-09-16, status=1, ipAttribution=)]
    2023-05-14 cnxcy
  2. [GetPortalCommentsPageByObjectIdResponse(id=1786130, encodeId=56391e861307d, content=<a href='/topic/show?id=e30813e89e2' target=_blank style='color:#2F92EE;'>#Pathogens#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13789, encryptionId=e30813e89e2, topicName=Pathogens)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Sun May 14 19:44:44 CST 2023, time=2023-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909345, encodeId=39081909345e6, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Mar 07 02:44:44 CST 2023, time=2023-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404791, encodeId=747f1404e91aa, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Fri Sep 16 04:44:44 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471718, encodeId=accc14e17186e, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Fri Sep 16 04:44:44 CST 2022, time=2022-09-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1786130, encodeId=56391e861307d, content=<a href='/topic/show?id=e30813e89e2' target=_blank style='color:#2F92EE;'>#Pathogens#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13789, encryptionId=e30813e89e2, topicName=Pathogens)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Sun May 14 19:44:44 CST 2023, time=2023-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909345, encodeId=39081909345e6, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Mar 07 02:44:44 CST 2023, time=2023-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404791, encodeId=747f1404e91aa, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Fri Sep 16 04:44:44 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471718, encodeId=accc14e17186e, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Fri Sep 16 04:44:44 CST 2022, time=2022-09-16, status=1, ipAttribution=)]
    2022-09-16 wincls
  4. [GetPortalCommentsPageByObjectIdResponse(id=1786130, encodeId=56391e861307d, content=<a href='/topic/show?id=e30813e89e2' target=_blank style='color:#2F92EE;'>#Pathogens#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13789, encryptionId=e30813e89e2, topicName=Pathogens)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=827b160, createdName=cnxcy, createdTime=Sun May 14 19:44:44 CST 2023, time=2023-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909345, encodeId=39081909345e6, content=<a href='/topic/show?id=8039e2512e8' target=_blank style='color:#2F92EE;'>#相互作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72512, encryptionId=8039e2512e8, topicName=相互作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Mar 07 02:44:44 CST 2023, time=2023-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1404791, encodeId=747f1404e91aa, content=<a href='/topic/show?id=1a4f4649925' target=_blank style='color:#2F92EE;'>#宿主#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46499, encryptionId=1a4f4649925, topicName=宿主)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/08904ED76550A0090DB220A7FB81D755/100, createdBy=78512492586, createdName=wincls, createdTime=Fri Sep 16 04:44:44 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471718, encodeId=accc14e17186e, content=<a href='/topic/show?id=c0132410554' target=_blank style='color:#2F92EE;'>#互作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24105, encryptionId=c0132410554, topicName=互作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dc87121468, createdName=ylz8405, createdTime=Fri Sep 16 04:44:44 CST 2022, time=2022-09-16, status=1, ipAttribution=)]
    2022-09-16 ylz8405

相关资讯

今年流感为什么如此严重且反季节?如何预防流感?

近日,广东各地发热门诊流感患者人数剧增。广东疾控流感监测数据显示,平均100个门诊病例中有7个都是流感病人,这提示广东已进入流感夏季高峰。一般都认为流感是冬春季节为主,事实上在中国南方,夏季同样是流感

Pediatrics:新冠大流行期间儿童的急性呼吸道疾病

2020 年 3 月至 4 月期间,美国 7 个城市的 ARI 病例以及儿童 RSV 和流感的比例迅速下降,这可能归因于针对新冠病毒采取的社区隔离措施。

Science : 流感疫苗局势出现了新挑战

理论上,由一种疫苗引发多个bnAbs(broadly neutralizing antibodies,广义中和抗体)攻击流感病毒的不同部位,或者更适应病毒的变化,可以帮助缓解耐药突变的问题。

Eur Respir J:新冠病毒和流感病毒感染的特异性宿主反应与基因特征

新冠肺炎患者肺部炎症、I型干扰素产生、凝血和血管生成相关基因显著上调。

夏宁邵教授团队发现靶向H1N1和H5N1流感病毒HA头部受体结合区的交叉广谱中和表位

禽流感病毒H5N1也是一种甲型流感病毒,人感染后病死率高达60%。

我国发现新型重组猪流感病毒H9N2,有感染人的可能

据中国疾病预防控制中心,近日,香港大学公共卫生学院发表的一项研究指出,在中国,H9N2禽流感病毒正在感染猪,并与猪流感病毒发生重组。依据已有研究,该病毒株具有人畜共患病传播的可能性。